المساهمون: Tang Xiaodong, Dr.

المصدر: A Prospective Randomized Phase Ⅱ Study of Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

المساهمون: Hua Wang, Professor

المصدر: Modified BFM-95 Regimen for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults:a Prospective Phase II Study
Wang K, Chen X, Wuxiao Z, Wang Z, Sun X, Zeng Z, Li S, Xia ZJ. Long-term outcomes of modified Berlin-Frankfurt-Munster-90 regimen in adults with T-lymphoblastic lymphoma: a single-center experience. Leuk Lymphoma. 2014 Aug;55(8):1800-5. doi: 10.3109/10428194.2013.828350. Epub 2014 Mar 7.

المؤلفون: GENG Jie, LI Hua, HE Sai

المصدر: Zhongguo linchuang yanjiu, Vol 37, Iss 3, Pp 375-378 (2024)

مصطلحات موضوعية: moxibustion, neiguan acupoint, breast cancer, chemotherapy, pirarubicin, dexrazoxane, myocardial damage, cardiac troponin, brain natriuretic peptide, cardiotoxicity, Medicine

وصف الملف: electronic resource

Relation: http://zglcyj.ijournals.cn/zglcyj/ch/reader/view_abstract.aspx?file_no=20240310; https://doaj.org/toc/1674-8182

URL الوصول: https://doaj.org/article/6951cdf4092c4d2b9b5210f26becd38a

المؤلفون: Lei Wang, Jiulong Ma, Chen Chen, Bin Lin, Sicong Xie, Weiwei Yang, Jiajia Qian, Yang Zhang

المصدر: Frontiers in Pharmacology, Vol 15 (2024)

مصطلحات موضوعية: isoquercitrin, Phlpp1/AKT/Bcl-2 signaling pathway, pirarubicin, apoptosis, oxidative damage, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1315001/full; https://doaj.org/toc/1663-9812

URL الوصول: https://doaj.org/article/ce9fc03685b44b788a038746a33e96c6

المؤلفون: CSPC Ouyi Pharmaceutical Co., Ltd.

المساهمون: Binghe Xu, Academician，Director of Department of Clinical Trial Center

المصدر: Adjuvant AC Followed by Albumin-bound Paclitaxel Versus AC Followed by Taxanes in Breast Cancer: a Prospective, Multi-center, Real-world Study

المؤلفون: Yang Zhang, Jiulong Ma, Shan Liu, Chen Chen, Qi Li, Meng Qin, Liqun Ren

المصدر: Journal of Ginseng Research, Vol 47, Iss 1, Pp 106-116 (2023)

مصطلحات موضوعية: Ginsenoside F1, Pirarubicin, Cardiotoxicity, Oxidative stress, Apoptosis, Botany, QK1-989

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S1226845322000860; https://doaj.org/toc/1226-8453

URL الوصول: https://doaj.org/article/5dd27e1637704b3f9bcc0ed829fd882c

المؤلفون: Kazuaki Taguchi, Keishi Yamasaki, Kenji Tsukigawa, Kindness Commey, Koji Nishi, Masaki Otagiri, Mina Sakuragi, Shuhei Imoto, Takashi Hasegawa

المصدر: Chemical and Pharmaceutical Bulletin. 2024, 72(1):21

المساهمون: Pin Zhang, Clinical Professor

المصدر: A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Efficacy and Safety of Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Platinum-based Neoadjuvant Chemotherapy

المؤلفون: Peking University Shougang Hospital, Chinese PLA General Hospital, Beijing Jishuitan Hospital, Xijing Hospital, Peking Union Medical College Hospital

المصدر: Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine, a Multicentre, Open-label, Randomised Phase 2 Trial
Frezza AM, Stacchiotti S, Gronchi A. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Med. 2017 Jun 2;15(1):109. doi: 10.1186/s12916-017-0872-y.
Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul;11(7):1276-85. doi: 10.1200/JCO.1993.11.7.1276.
Jelic S, Kovcin V, Milanovic N, Babovic N, Kreacic M, Ristovic Z, Vlajic M, Filipovic-Ljeskovic I. Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer. 1997 Feb;33(2):220-5. doi: 10.1016/s0959-8049(96)00297-3.
Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, Blay JY, Frisch J, Van Glabbeke M, Hermans C, Van Oosterom A, Tursz T, Verweij J. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000 Jul;18(14):2676-84. doi: 10.1200/JCO.2000.18.14.2676.
Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995 Jul;13(7):1537-45. doi: 10.1200/JCO.1995.13.7.1537.
Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30;388(10043):488-97. doi: 10.1016/S0140-6736(16)30587-6. Epub 2016 Jun 9. Erratum In: Lancet. 2016 Jul 30;388(10043):464. doi: 10.1016/S0140-6736(16)31156-4.
Bui-Nguyen B, Butrynski JE, Penel N, Blay JY, Isambert N, Milhem M, Kerst JM, Reyners AK, Litiere S, Marreaud S, Collin F, van der Graaf WT; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC/STBSG) and the Sarcoma Alliance for Research through Collaboration (SARC). A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. Eur J Cancer. 2015 Jul;51(10):1312-20. doi: 10.1016/j.ejca.2015.03.023. Epub 2015 Apr 23.
Schoffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Grunwald V, Sciot R, Dumez H, Blay JY, Le Cesne A, Wanders J, Hayward C, Marreaud S, Ouali M, Hohenberger P; European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011 Oct;12(11):1045-52. doi: 10.1016/S1470-2045(11)70230-3. Epub 2011 Sep 19. Erratum In: Lancet Oncol. 2015 Sep;16(9):e427. doi: 10.1016/S1470-2045(15)00236-3.
Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973 Aug;32(2):302-14. doi: 10.1002/1097-0142(197308)32:23.0.co;2-2. No abstract available.
Vondrakova D, Malek F, Ostadal P, Vranova J, Miroslav P, Schejbalova M, Neuzil P. Correlation of NT-proBNP, proANP and novel biomarkers: copeptin and proadrenomedullin with LVEF and NYHA in patients with ischemic CHF, non-ischemic CHF and arterial hypertension. Int J Cardiol. 2011 Aug 4;150(3):343-4. doi: 10.1016/j.ijcard.2011.05.029. Epub 2011 Jun 2. No abstract available.
Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710-7. doi: 10.7326/0003-4819-91-5-710.
Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2014 Oct-Dec;10(4):853-8. doi: 10.4103/0973-1482.139267.
Nielsen OS, Dombernowsky P, Mouridsen H, Daugaard S, Van Glabbeke M, Kirkpatrick A, Verweij J. Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group. Sarcoma. 2000;4(1-2):31-5. doi: 10.1155/S1357714X00000062.
Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, van Oosterom AT, Clemons MJ, Kamby C, Hermans C, Whittaker J, Donato di Paola E, Verweij J, Nielsen S. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001 May;37(7):870-7. doi: 10.1016/s0959-8049(01)00050-8.
Bafaloukos D, Papadimitriou C, Linardou H, Aravantinos G, Papakostas P, Skarlos D, Kosmidis P, Fountzilas G, Gogas H, Kalofonos C, Dimopoulos AM. Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group. Br J Cancer. 2004 Nov 1;91(9):1639-44. doi: 10.1038/sj.bjc.6602148.
Poveda A, Lopez-Pousa A, Martin J, Del Muro JG, Bernabe R, Casado A, Balana C, Sanmartin O, Menendez MD, Escudero P, Cruz J, Belyakova E, Menendez D, Buesa JM. Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma. 2005;9(3-4):127-32. doi: 10.1080/13577140500287024.
Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002 Mar;38(4):543-9. doi: 10.1016/s0959-8049(01)00398-7.

المصدر: Single-center, Open, Non-randomized, Phase II Prospective Study of Apatinib Combined With Chemotherapy in the Treatment of Unresectable Soft Tissue Sarcoma

المؤلفون: Shanghai Pudong Hospital, Shanghai Pudong New Area Gongli Hospital

المساهمون: Yiran Huang, Director of Urology department in Renji Hospital

المصدر: Prospective Randomized Phase II Trial: Single Instillation Versus Long-term Prophylactic Intravesical Instillation of Pirarubicin in the Prevention of Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma

المساهمون: Chengcheng Liao, Director, Principal Investigator, Clinical Professor

المصدر: Systemic Chemotherapy VersusTranscatheter Arterial Chemoembolization As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)
Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013 Oct 1;31(28):3501-8. doi: 10.1200/JCO.2012.44.5643. Epub 2013 Aug 26.
Li L, Sun F, Chen AJ, Li XY, Hu MD, Ran JH, Tang JH. [Capecitabine combined with TACE for advanced liver cancer]. Zhonghua Zhong Liu Za Zhi. 2004 Sep;26(9):565-6. Chinese.
Mabed M, Esmaeel M, El-Khodary T, Awad M, Amer T. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care (Engl). 2009 Sep;18(5):492-9. doi: 10.1111/j.1365-2354.2008.00984.x.

المصدر: Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic Drugs Based on Organ-like Culture

المساهمون: Weisong Cai, Professor

المصدر: A Multicenter, Randomized, Double-blind, Prospective Study to Evaluate the Efficacy and Safety of Vincristine, Dactinomycin/Cyclophosphamide Combination Therapy Combined With Liposomal Doxorubicin/Doxorubicin/Pharmorubicin/Pirarubicin in 0.5-14 Year Old Children With Nephroblastoma.

المؤلفون: Ohnmar Myint, Sakornniya Wattanapongpitak, Suchart Kothan, Chatchanok Udomtanakunchai, Singkome Tima, Montree Tungjai

المصدر: Toxicology Reports, Vol 9, Iss , Pp 1443-1451 (2022)

مصطلحات موضوعية: 4-hydroxybenzoic acid, 4-hydroxy-3-methoxybenzoic acid, Multidrug resistance, P-glycoprotein, Pirarubicin, Cancer, Toxicology. Poisons, RA1190-1270

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2214750022001536; https://doaj.org/toc/2214-7500

URL الوصول: https://doaj.org/article/477a748a314d4345974af23cdd2447b3

المؤلفون: Zhenyu Nie, Yuanhui Gao, Mei Chen, Yanling Peng, Na Guo, Hui Cao, Denggao Huang, Xin Gao, Shufang Zhang

المصدر: Cancers ; Volume 15 ; Issue 9 ; Pages: 2487

مصطلحات موضوعية: CRISPR/dCas9-SAM, bladder cancer, pirarubicin, drug resistance, AKR1C1

وصف الملف: application/pdf

Relation: Molecular Cancer Biology; https://dx.doi.org/10.3390/cancers15092487

الاتاحة: https://doi.org/10.3390/cancers15092487

المؤلفون: Yutaka Kato, Hiroshi Kawaguchi, Naoki Sakata, Satoshi Ueda, Munehiro Okano, Yuuki Nishino, Masako Ryujin, Yutaka Takemura, Tsukasa Takemura, Keisuke Sugimoto, Satoshi Okada

المصدر: Children; Volume 10; Issue 5; Pages: 871

مصطلحات موضوعية: pirarubicin, low-dose chemotherapy, neuroblastoma, early infant, stage MS

وصف الملف: application/pdf

Relation: Oncology and Hematology; https://dx.doi.org/10.3390/children10050871

الاتاحة: https://doi.org/10.3390/children10050871

المؤلفون: Yajun Mou, Jianjun Huang, Wenxiu Yang, Yu Wan, Zhenhong Pu, Junhong Zhang, Jinting Liu, Qing Li, Peipei Zhang, Yuan Tian, Hui Yang, Yi Cui, Pingsheng Hu, Xiaowei Dou

المصدر: Frontiers in Oncology, Vol 12 (2022)

مصطلحات موضوعية: primary cells, breast cancer, pirarubicin, doxorubicin, sensitivity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2022.1023391/full; https://doaj.org/toc/2234-943X

URL الوصول: https://doaj.org/article/ad28c0effcb74d1ba68dbcf9e29815db

المؤلفون: Xiaoliang Sun, Xinhong Song, Peng Guo, Dong Zhang, Shishuai Zuo, Kang Leng, Yun Liu, Haiyang Zhang

المصدر: Frontiers in Bioengineering and Biotechnology, Vol 10 (2022)

مصطلحات موضوعية: bladder perfusion, pirarubicin, chitosan, sustained release, tight junction, occludin, Biotechnology, TP248.13-248.65

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fbioe.2022.958072/full; https://doaj.org/toc/2296-4185

URL الوصول: https://doaj.org/article/dacaa15c87ca4177ab471ebaeb43f524

المؤلفون: Shiro Saito, Hisaki Aiba, Satoshi Yamada, Hideki Okamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Takanobu Otsuka, Hideki Murakami

المصدر: BMC Cancer, Vol 20, Iss 1, Pp 1-6 (2020)

مصطلحات موضوعية: Chemotherapy, Pirarubicin, Ifosfamide, Etoposide, Soft tissue sarcoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: http://link.springer.com/article/10.1186/s12885-020-07378-z; https://doaj.org/toc/1471-2407

URL الوصول: https://doaj.org/article/0596c91250484339a18bca292edc5b43